IP Verse

Treatment Of Hidradenitis Suppurativa Using Jak Inhibitors - EP3773593

EP3773593

INCYTE
Application Number
EP19722308A
Filing Date
Mar 29, 2019
Status
Granted And Under Opposition
Apr 12, 2024
Grant Date
May 15, 2024
External Links
Slate, Register, Google Patents

Bibliography

The patent EP3773593B1 was granted to Incyte on May 15, 2024 following the initial filing on Mar 29, 2019 under the application number EP19722308A . The current legal status of the patent is Granted And Under Opposition.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

HAMM & WITTKOPPFeb 14, 2025ADMISSIBLE

Patent Citations (36) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20090578491-
DESCRIPTIONUS2010298334
DESCRIPTIONUS2011059951
DESCRIPTIONUS2011224190
DESCRIPTIONUS2012149681
DESCRIPTIONUS2012149682
DESCRIPTIONUS2013018034
DESCRIPTIONUS2013045963
DESCRIPTIONUS2013060026
DESCRIPTIONUS2014005166
DESCRIPTIONUS2014121198
DESCRIPTIONUS2014256941
DESCRIPTIONUS2014343030
DESCRIPTIONUS2015344497
DESCRIPTIONUS5521184
DESCRIPTIONUS7598257
DESCRIPTIONUS8722693
DESCRIPTIONUS9249149
DESCRIPTIONUS9540367
DESCRIPTIONWO0009495
DESCRIPTIONWO0053595
DESCRIPTIONWO0114402
DESCRIPTIONWO0164655
DESCRIPTIONWO0200196
DESCRIPTIONWO03024967
DESCRIPTIONWO03037347
DESCRIPTIONWO03099771
DESCRIPTIONWO2004005281
DESCRIPTIONWO2004046120
DESCRIPTIONWO2004056786
DESCRIPTIONWO2004080980
DESCRIPTIONWO2005028444
DESCRIPTIONWO2006056399
INTERNATIONAL-SEARCH-REPORTWO2017143014
INTERNATIONAL-SEARCH-REPORTWO2019090143
OPPOSITIONUS9249149

Non-Patent Literature (NPL) Citations (32) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- Adv Pharmacol., (20000000), vol. 47, pages 113 - 74-
DESCRIPTION- A. KEREKES, J. Med. Chem., (20110000), vol. 54, pages 201 - 210-
DESCRIPTION- BOUDNY, V.KOVARIK, J., Neoplasm., (20020000), vol. 49, pages 349 - 355-
DESCRIPTION- BOWMAN, T. et al., Oncogene, (20000000), vol. 19, pages 2474 - 2488-
DESCRIPTION- FLEX, J Exp Med, (20080000), vol. 205, pages 751 - 8-
DESCRIPTION- FONESCA et al., Autoimmunity Reviews, (20090000), vol. 8, pages 538 - 42-
DESCRIPTION- GUSCHIN et al., Embo J, (19950000), vol. 14, page 1421-
DESCRIPTION- HOFFMAN et al., PLOS One, (20180928), URL: https://doi.org/10.1371/journalpone.0203672-
DESCRIPTION- JCI, vol. 113, pages 1664 - 1675-
DESCRIPTION- JOCHEN ZIMMERMANN, Angew. Chem. Int. Ed., (20070000), pages 7744 - 7765-
DESCRIPTION- Journal of Pharmaceutical Science, (19770000), vol. 66, page 2-
DESCRIPTION- LEVIN et al., Cancer Cell, (20050000), vol. 7, pages 387 - 397-
DESCRIPTION- MULLIGHAN, Proc Natl Acad Sci U S A., (20090000), vol. 106, pages 9414 - 8-
DESCRIPTION- ORTMANN, R. A.T. CHENG et al., Arthritis Res, (20000000), vol. 2, no. 1, pages 16 - 32-
DESCRIPTION- PARK, Analytical Biochemistry, (19990000), vol. 269, pages 94 - 104-
DESCRIPTION- Remington's Pharmaceutical Sciences, Mack Publishing Company, (19850000), page 1418-
DESCRIPTION- RODIG, S. J.M. A MERAZ et al., Cell, (19980000), vol. 93, no. 3, pages 373 - 83-
DESCRIPTION- R. XU, J. Label Compd. Radiopharm., (20150000), vol. 58, pages 308 - 312-
DESCRIPTION- SMOLEN et al., Lancet, (20080000), vol. 371, page 987-
INTERNATIONAL-SEARCH-REPORT- HARUMI OCHI ET AL, "The effect of oral clindamycin and rifampicin combination therapy in patients with hidradenitis suppurativa in Singapore", CLINICAL, COSMETIC AND INVESTIGATIONAL DERMATOLOGY, (20180101), Volume 11, doi:10.2147/CCID.S136730, pages 37 - 39, XP055600542 [A] 1-24 * table - *
OPPOSITION- Anonymous, "2020 Third Quarter Financial and Corporate Update", Incyte, (20201105), Incyte, URL: https://investor.incyte.com/static-files/f24942e0-869b-459a-8ae4-61f1baaea721, XP093293507-
OPPOSITION- Anonymous, "EMEA/H/C/000481/II/0137, Assessment report", Committee for Medicinal Products for Human Use (CHMP), Committee for Medicinal Products for Human Use (CHMP), (20150625), pages 1 - 124, XP093262169-
OPPOSITION- Anonymous, "emea/h/c/002464, CHMP assessment report ", Committee for Medicinal Products for Human Use (CHMP), (20120419), pages 1 - 84, XP093262181-
OPPOSITION- D08: patentees submission of May 21st , 2021, during the examination procedure-
OPPOSITION- Porter Martina L, Ferreira-Cornwell M Celeste, Wang Mingyue, Nawaz Haq, Gooderham Melinda J, "Ruxolitinib Cream for Mild-to-Moderate Hidradenitis Suppurativa: 32-Week Data From a Randomized Phase 2 Study", European Academy of Dermatology and Venereology Congress, (20240928), pages 1 - 13, XP093251491-
OPPOSITION- Saunte Ditte Marie Lindhardt, Jemec Gregor Borut Ernst, "Hidradenitis Suppurativa : Advances in Diagnosis and Treatment", JAMA, Clyancourt Corporation, Chicago, IL, Chicago, IL, (20171128), vol. 318, no. 20, doi:10.1001/jama.2017.16691, ISSN 0098-7484, pages 2019 - 2032, XP093262158
OPPOSITION- Katharina Welsch, "Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors", Eur.J. Immunol. , (2017), vol. 47, doi:10.1002/eji.201646680, XP071228283
OPPOSITION- Sabat R. et al, "Acne inversa/hidradenitis suppurativa: An update", HAUTARZT, SPRINGER VERLAG, BERLIN., DE, DE , (20171120), vol. 68, no. 12, doi:10.1007/s00105-017-4082-5, ISSN 0017-8470, pages 999 - 1006, XP036389157
OPPOSITION- Kimball Alexa B, et al, "Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa", The NEW ENGLAND JOURNAL of MEDICINE, (20160804), vol. 375, no. 5, doi:10.1056/NEJMoal504370, pages 422 - 434, XP093262177
OPPOSITION- Alavi Afsaneh, Hamzavi Iltefat, Brown Kurt, Santos Leandro L., Zhu Zhaoyin, Liu Huiqing, Howell Michael D., Kirby Joslyn S., "Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies*", British journal of dermatology (1951), Wiley, (20220501), vol. 186, no. 5, doi:10.1111/bjd.20969, ISSN 0007-0963, pages 803 - 813, XP093293508
OPPOSITION- C. C. Zouboulis, "European S1 guideline for the treatment of hidradenitis supprurativa/acne inversa", European Academy of Dermatology and Venereology, (2015), vol. 29, doi:10.1111/jdv.12966, XP055962586
OPPOSITION- John W. Frew, "A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa", F1000Research, (20181213), vol. 7, doi:10.12688/f1000research.17267.1, XP055708017

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents